{"id":5073,"date":"2026-10-16T10:46:12","date_gmt":"2026-10-16T10:46:12","guid":{"rendered":"https:\/\/nhdbio.com\/?p=5073"},"modified":"2026-10-16T10:46:12","modified_gmt":"2026-10-16T10:46:12","slug":"ll37-ferritin-fusion-mouse-sepsis-delivery","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/ll37-ferritin-fusion-mouse-sepsis-delivery\/","title":{"rendered":"LL-37\u2013Fusion de ferritine : Qu'est-ce qui change lorsque la d\u00e9livrance change ?"},"content":{"rendered":"
\n

LL-37\u2013Fusion \u00e0 la ferritine : qu'est-ce qui change quand le mode d'administration change ?<\/h2>\n

Understand the difference between free LL-37 and an FTL\u2013LL-37 fusion protein in a mouse sepsis study.<\/p>\n

\"LL-37\u2013Fusion
Illustration \u00e9ditoriale, pas une photographie exp\u00e9rimentale.<\/figcaption><\/figure>\n

What the researchers constructed<\/h3>\n

The paper genetically fused LL-37 to the C-terminus of ferritin light chain, FTL, producing a fusion protein designated FL. This is a newly constructed protein material, not a mixture of two powders. Ferritin contributes structural and recognition-related properties; LL-37 supplies the antimicrobial-peptide component being studied.<\/p>\n

Why delivery was part of the question<\/h3>\n

Activity in a test tube does not establish stability in a biological environment or accumulation at the intended site. The abstract discusses limitations including proteolytic degradation of free LL-37. The fusion design attempts to address both persistence and delivery, rather than simply changing the peptide name.<\/p>\n

\"Linking
Study schematic. The fusion protein and free LL-37 are different materials; their results are not interchangeable.<\/figcaption><\/figure>\n

What SR-A contributes<\/h3>\n

SR-A is a scavenger receptor. The study uses recognition of FTL by SR-A to investigate targeted delivery. Receptor recognition is an interaction opportunity, not proof that material reaches only one location. Uptake, distribution, controls and other experiments are needed to evaluate the proposed delivery explanation.<\/p>\n

What the mouse findings support<\/h3>\n

In a mouse sepsis model, FL showed better antibacterial and anti-inflammatory outcomes than free LL-37 and partly reduced organ damage. The paper also reported the safety endpoints tested. These are findings for a particular formulation and animal model, not established human safety or proof that all ferritin\u2013peptide fusions behave similarly.<\/p>\n

Keep the comparison groups separate<\/h3>\n

The diagram shows the FTL\u2013LL-37 fusion, receptor recognition and mouse model without inventing unverified quantitative effects. When reading the paper, distinguish free peptide, carrier, fusion protein and model controls. Otherwise, effects associated with the complete delivery system may be incorrectly attributed to free LL-37 alone.<\/p>\n

A free peptide order is not a fusion-protein order<\/h3>\n

The LL-37 page is an entry point for free research-peptide enquiries. A project requiring FL needs separate construct, expression and characterization requirements. This article does not state that NHD supplies the fusion protein or has performed the same experiments.<\/p>\n

R\u00e9f\u00e9rences<\/h3>\n